GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » Selling, General, & Admin. Expense

Hyloris Pharmaceuticals (LTS:0AB6) Selling, General, & Admin. Expense : €5.65 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Hyloris Pharmaceuticals's selling, general, & admin. expense for the six months ended in Dec. 2023 was €3.16 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was €5.65 Mil.


Hyloris Pharmaceuticals Selling, General, & Admin. Expense Historical Data

The historical data trend for Hyloris Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Selling, General, & Admin. Expense Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 0.81 2.19 2.90 3.52 5.65

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 1.27 2.24 2.49 3.16

Competitive Comparison of Hyloris Pharmaceuticals's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Selling, General, & Admin. Expense falls into.



Hyloris Pharmaceuticals Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €5.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyloris Pharmaceuticals  (LTS:0AB6) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Hyloris Pharmaceuticals Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (LTS:0AB6) Headlines

No Headlines